评估阿尔茨海默氏症老化向方法:我们所知道的和未来的
Pratik Prashant Doshi1, Sakshee Hemant Desale1, Aarti Ashok Khutale1
1Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune, 411018, India.
Ageing research reviews
|January 21, 2026
概括
细胞衰老,衰老的标志,驱动阿尔茨海默病 (AD) 的进展. 老化剂,清除衰老细胞的药物,通过减少神经炎症和改善认知,在临床前的AD模型中表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是最常见的痴呆症,传统上通过向粉样蛋白-β (Aβ) 和病理来治疗.
- 细胞衰老,以衰老相关的分泌表型 (SASP) 为特征,越来越被认为是AD病变发生的关键驱动因素.
- 衰老细胞积聚在老化的大脑中,释放促炎和神经毒性因素,促进神经退行和认知衰退.
研究的目的:
- 审查细胞衰老在阿尔茨海默氏症病原发生中的作用.
- 探索 senolytics 和 senomorphic 策略在AD中的治疗潜力.
- 在临床AD管理中概述老年治疗药物的挑战和未来方向.
主要方法:
- 综合当前关于AD细胞衰老的证据.
- 对老化剂 (如达沙替尼,奎尔塞丁,菲塞,纳维托克拉克斯) 的临床前研究的综述.
- 对针对衰老的干预措施的早期人类研究的分析.
主要成果:
- 在临床前阿尔茨海默病模型中,老年药物显示出有效性,减少神经炎症并改善认知表现.
- 与衰老相关的分子变化可能会影响血脑屏障的完整性,而老化药物显示出部分恢复的潜力.
- 早期的人类研究表明可行性,但临床转化受限于中枢神经系统透,剂量,安全性和生物标志物开发方面的挑战.
结论:
- 细胞衰老是阿尔茨海默病的关键治疗目标.
- 老年治疗药物为现有的AD疗法提供了一个有前途的补充方法,提供了一个多机制的策略.
- 需要进一步的研究来克服临床翻译的挑战,并将老年化药物整合到AD管理中.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...